A Message from the Purdue Pharma (Canada) Leadership Team
While prescription opioid medicines remain a safe and effective treatment for patients who are appropriately selected and monitored, like all medicines, prescription opioid medicines have risks, including addiction. Unfortunately, misuse and abuse and diversion of pain medications can lead to tragic consequences, including addiction, overdose and death.
At the same time, according to the Canadian Pain Society, pain is the most common reason for seeking healthcare in Canada. Patients who suffer from chronic pain cannot be ignored.
This complex public health issue is a matter of deep concern to Purdue Pharma (Canada). All stakeholders, including the pharmaceutical industry, have a role to play in providing practical and sustainable solutions.
Purdue Pharma (Canada) supports a research-driven approach to managing pain that may or may not include available prescription products, in combination with other effective pharmacological and non-pharmacological treatments and plans to continue our activities which include:
- – Providing information and tools to healthcare professionals through our field teams. Examples include: the Patient Agreement & Opioid Risk Tool and The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain issued by the Michael G. DeGroote National Pain Centre at McMaster University, funded by Health Canada and the Canadian Institutes of Health Research; and,
- – Supporting accredited third-party approved education programs on topics such as Approaches to Responsible Opioid Prescribing, The 2017 Canadian Opioid Guidelines, Non-Pharma Treatment Options and Risk Mitigation Strategies.
In June 2017, Purdue Pharma (Canada) and nine other members of Innovative Medicines Canada voluntarily published aggregated sums of their payments (including services such as speaking) to Canadian healthcare professionals (HCPs) and Healthcare Organizations (HCOs).
This was a first step. Bringing greater transparency to these valuable and well-regulated relationships we hope to increase understanding of the research-based pharmaceutical industry’s collaboration across the healthcare sector, and contribute to enhancing trust and value for patients, as well as our healthcare system.
All transfers of value by Purdue Pharma (Canada) are in compliance with the IMC Code of Ethical Practices.
Purdue Pharma (Canada) has always marketed its products in line with the Health Canada approved product monograph and in compliance with all relevant rules, regulations and codes, including the Food and Drugs Act and the Pharmaceutical Advertising Advisory Board (PAAB) Code.
About Purdue Pharma (Canada)
Purdue Pharma (Canada) is a research-based pharmaceutical and consumer healthcare company which has operated in Canada for over 60 years. Its 400 employees are committed to improving the health and quality of life of Canadians. The company has a broad portfolio of prescription and non-prescription medications including: prescription treatments for pain, attention deficit hyperactivity disorder (ADHD), chemotherapy-induced nausea and vomiting (CINV), various ophthalmic conditions and Consumer Healthcare products. The company supports evidence-based education for the safe use of its products. Its headquarters, located in Pickering, ON, includes integrated research & development, formulation and manufacturing operations. The company is a member of Innovative Medicines Canada and complies with the association’s Code of Ethical Practices. Purdue Pharma (Canada) is part of an independently associated network of companies and is operated independently from Purdue Pharma L.P. in the United States.